Nature Reviews Drug Discovery contents January 2016 Volume 15 Number 1 pp 1-73

If you are unable to see the message below, click here to view.

Advertisement
Infectious disease control and elimination The Diagnostics Modelling Consortium was established in 2013 to facilitate the integration of diagnostic data into models of disease transmission dynamics. In this supplement, the Consortium and its partners report on the latest research outcomes across several major diseases.  Available free online. Financial support for publication has been provided by the Bill & Melinda Gates Foundation
TABLE OF CONTENTS
January 2016 Volume 15 Number 1
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Reviews Correspondence Also this month  Featured article: Targeting voltage-gated calcium channels in neurological and psychiatric diseases Gerald W. Zamponi
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Comment: Towards a hit for every target Steve Rees, Philip Gribbon, Karen Birmingham, William P. Janzen & Garry Pairaudeau p1 | doi:10.1038/nrd.2015.19 Technological advances coupled with novel collaborative strategies for compound sourcing and management are poised to transform the utility of high-throughput screening. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Making way for maternal immunization Asher Mullard p3 | doi:10.1038/nrd.2015.38 Just weeks after an FDA advisory meeting on the use of vaccines in pregnant women to protect newborn babies, Novavax has launched the first ever Phase III trial of a vaccine for maternal immunization licensure. PDF
Age of antibody therapeutics dawns for multiple myeloma Katie Kingwell p5 | doi:10.1038/nrd.2015.39 Approvals of Janssen's daratumumab and Bristol-Myers Squibb's elotuzumab cap a stellar year for multiple myeloma therapies, providing two new mechanisms of action and prompting a slew of combination trials. PDF
NEWS IN BRIEF Industry R&D returns slip Asher Mullard p7 | doi:10.1038/nrd.2015.41 PDF
FDA approves drug from transgenic chicken Asher Mullard p7 | doi:10.1038/nrd.2015.42 PDF
Industry gets mixed transparency grades Asher Mullard p7 | doi:10.1038/nrd.2015.43 PDF
BIOBUSINESS BRIEFS Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape Jeannette L. A. Fiala & Drew Lowery p8 | doi:10.1038/nrd.2015.11 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q1 2016 Edny Inui p9 | doi:10.1038/nrd.2015.25 PDF
AN AUDIENCE WITH Vas Narasimhan p10 | doi:10.1038/nrd.2015.33 Vas Narasimhan, global head of development at Novartis, discusses his plans to increase the efficiency and reduce the cost of trial execution. PDF
FROM THE ANALYST'S COUCH Monoclonal antibody biosimilars Natasha Udpa & Ryan P. Million p13 | doi:10.1038/nrd.2015.12 With biosimilar monoclonal antibodies now entering the market and a surge of biosimilars expected once the patents for major pioneer products expire, this article analyses experiences so far and future market dynamics. PDF
RESEARCH HIGHLIGHTS Top G protein-coupled receptors: Illuminating orphan GPCRs p15 | doi:10.1038/nrd.2015.32 PDF Stroke: GDF10 spurs on axonal sprouting after stroke p16 | doi:10.1038/nrd.2015.27 PDF Cancer: Engineered T cells gain access to pancreatic tumours p16 | doi:10.1038/nrd.2015.40 PDF Neurodevelopmental disorders: Preventative treatment for infantile epilepsy p17 | doi:10.1038/nrd.2015.26 PDF Antibacterial drugs: Antibody-antibiotic conjugate tracks down hidden S. aureus p18 | doi:10.1038/nrd.2015.24 PDF IN BRIEF Cancer: Disrupting protein homeostasis | Alzheimer disease: Aβ-targeting antibodies aggravate neuronal dysfunction | Cancer: Novel PDL1 inhibitor identified | Antiviral drugs: HSP70 inhibitor blocks virus replication PDF Drug Discovery JOBS of the week Postdoctoral Fellow Dana-Farber Cancer Institute (DFCI) Post Doc (m / f) – Computational Biology Boehringer Ingelheim Postdoctoral Candidate / Research Associate Texas Biomedical Research Institute Research Fellow-Translational Science in AAV Mayo Clinic Associate / Full Professor - Biopharmaceutical Sciences University of Illinois More Science jobs from Drug Discovery EVENT UK Breast Cancer Research Symposium 2016 22.07.16 London, UK More science events from
Advertisement
Nature Genetics and Nature Reviews Cancer present: Nuclear Reprogramming and the Cancer Genome 2016 Sponsored by CapitalBio Corporation February 21-23, 2016 | La Jolla, CA, USA Register now!
REVIEWS		Top
Targeting voltage-gated calcium channels in neurological and psychiatric diseases Gerald W. Zamponi p19 | doi:10.1038/nrd.2015.5 Dysfunction of voltage-gated calcium channels is associated with a variety of neurological and psychiatric conditions. Several drugs that block these channels are already in clinical use, with new agents currently in development. Here, Zamponi highlights the functions of voltage-gated calcium channels and assesses their potential as therapeutic targets for nervous system disorders. Abstract | Full Text | PDF
Targeting key proximal drivers of type 2 inflammation in disease Namita A. Gandhi, Brandy L. Bennett, Neil M. H. Graham, Gianluca Pirozzi, Neil Stahl & George D. Yancopoulos p35 | doi:10.1038/nrd4624 Inflammatory conditions such as asthma, atopic dermatitis and chronic sinusitis with nasal polyps are caused by type 2 inflammation. In this Review, Gandhi et al. explore the idea that these conditions can be treated by targeting the common proximal drivers of type 2 inflammation, which include interleukin-4 (IL-4), IL-5 and IL-13, and discuss the supporting clinical evidence as well as candidate drugs in development. Abstract | Full Text | PDF
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 Chiara Degirolamo, Carlo Sabba & Antonio Moschetta p51 | doi:10.1038/nrd.2015.9 As critical regulators of glucose and lipid metabolism, as well as vitamin D and phosphate homeostasis, the endocrine fibroblast growth factors (FGFs) have therapeutic potential in various chronic human diseases. Here, Moschetta and colleagues discuss the physiological roles of FGF19, FGF21 and FGF23, focusing on recent advances and the associated challenges in their therapeutic exploitation. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Identification and validation of biomarkers for autism spectrum disorders Eva Loth, Will Spooren, Lindsay M. Ham, Maria B. Isaac, Caroline Auriche-Benichou, Tobias Banaschewski, Simon Baron-Cohen, Karl Broich, Sven Bölte, Thomas Bourgeron, Tony Charman, David Collier, Fernando de Andres-Trelles, Sarah Durston, Christine Ecker, Andre Elferink, Marion Haberkamp, Robert Hemmings, Mark H. Johnson, Emily J. H. Jones, Omar S. Khwaja, Sabine Lenton, Luke Mason, Valentina Mantua, Andreas Meyer-Lindenberg, Michael V. Lombardo, Laurence O'Dwyer, Koichi Okamoto, Gahan J. Pandina, Luca Pani, Antonio M. Persico, Emily Simonoff, Sitra Tauscher-Wisniewski, Jordi Llinares-Garcia, Spiros Vamvakas, Steve Williams, Jan K. Buitelaar & Declan G. M. Murphy p70 | doi:10.1038/nrd.2015.7 Full Text | PDF | Supplementary information
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.